Edison Investment Research - SCANDION ONCOLOGY A/S (SCOL) Scandion Oncology - Chemotherapy overcoming drug resistance

Report

Edison Investment Research

Sean Conroy

Scandion Oncology - Chemotherapy overcoming drug resistance

Scandion Oncology is a Danish biotechnology company that specialises in developing drugs to reverse chemotherapy resistance. Its lead asset, SCO-101, is being investigated as an add-on therapy to existing treatments in metastatic colorectal cancer (mCRC) and unresectable pancreatic cancer (PC). Management’s clinical programme is spearheaded by the Phase II CORIST study in FOLFIRI-resistant mCRC, from which we expect crucial proof-of-concept results in Q322. The company is also pursuing the Phase Ib PANTAX trial in PC. Assuming proof-of-concept is met, the positioning of SCO-101 in higher lines of mCRC treatment will be essential to maximise value, in our view. We value Scandion Oncology at SEK586.5m or SEK18.3 per share.

20/06/2022 1 EN

Underlying

SCANDION ONCOLOGY A/S

Scandion Oncology A/S. Scandion Oncology A/S is a manufacturer of biological products. The Company was founded in May 2017 and is located in Copenhagen, Denmark. It focuses on modern onclogy, the treatment of cancers that have developed resistance to chemotherapy.

See profile

DK0061031895 Denmark

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Edison Investment Research

Scandion Oncology - An active quarter with AML plans in the mix

Q123 has been an active quarter for Scandion Oncology with completion of the Phase 1b PANTAX (dose-finding) study and management’s decision to expand the scope of SCO-101 into acute myeloid leukaemia (AML). With many upcoming catalysts, including an update on AML preclinical work in H223, top-line results for CORIST part 3 in H223, and full top-line data for PANTAX by H124, if favourable, we expect material progression of the company’s pipeline. Scandion reported an operating loss of DKK12.0m in Q123 (vs DKK16.3m in Q122) mainly due lower R&D expenses, reflecting the impact of cost control mea...

May 30, 2023 May 30, 2023 1 EN

Edison Investment Research

Scandion Oncology - PANTAX Phase I trial meets primary endpoint

Scandion Oncology has announced that the Phase Ib PANTAX trial has concluded and reached its primary endpoint. This study (n=22) evaluated SCO-101, the company’s lead asset, as an add-on therapy for patients with advanced pancreatic cancer (PC). SCO-101, in combination with the chemotherapy agents gemcitabine and nab-paclitaxel, demonstrated a favourable safety and tolerability profile and a maximum tolerated dose (MTD) was established at 200mg for six consecutive days every two weeks. Management has communicated that a more detailed analysis on the full data will be conducted in due course, b...

April 3, 2023 April 3, 2023 1 EN

Edison Investment Research

Scandion Oncology - Expanding SCO-101 into AML

In the recent management conference call to summarise the FY22 results, Scandion Oncology announced plans to expand SCO-101, its lead asset, into acute myeloid leukaemia (AML). The company plans to share certain details on the preclinical data package in H223, which we view as a significant catalyst, provided the data continue to be supportive. SCO-101 is also progressing as planned in the Phase II CORIST trial in metastatic colorectal cancer (mCRC), with readouts expected in Q323, and in the Phase Ib PANTAX trial in pancreatic cancer (PC), with readouts expected in H123.

March 29, 2023 March 29, 2023 1 EN

Manx Financial Group - Termination of coverage

Edison Investment Research is terminating coverage on Manx Financial Group (MFX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 10, 2025 March 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

musicMagpie - Termination of coverage

Edison Investment Research is terminating coverage on musicMagpie (MMAG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 5, 2025 March 5, 2025 1 EN

Kate Heseltine

Kate Heseltine

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Scandion Oncology - Chemotherapy overcoming drug resistance

Scandion Oncology - An active quarter with AML plans in the mix

Scandion Oncology - PANTAX Phase I trial meets primary endpoint

Scandion Oncology - Expanding SCO-101 into AML

Manx Financial Group - Termination of coverage

musicMagpie - Termination of coverage

Topps Tiles - Accelerating growth through Q125

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe